In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Amgen Inc.

www.amgen.com

Latest From Amgen Inc.

Asia Deal Watch: Strides Obtains 18 US ANDAs From Pharmaceutics

Deal news from Strides Pharma, Pharmaceutics Intl., Cipla, Wanbury, AstraZeneca, Syntekabio, Arctoris, Mundipharma, Samsung Bioepis…

Deals Business Strategies

The Only Way Is Nasdaq – Part One

The US Nasdaq exchange has become the only option for ambitious UK and European biotechs.

Business Strategies C-Suite Speaks

A Positive Outlook For Deals, With Election Year Caveats

Industry advisers at the BIO CEO & Investor meeting remained optimistic about the pharmaceutical deal environment in 2020 – even with the uncertainty around a looming US election year. 
Deals Market Intelligence

FDA Guides On Adding Biosimilar Indications

Sponsors may submit supplemental applications for additional indications in advance so that approval will coincide with expiration of a reference product’s exclusivity or patent protection, new draft guidance states; agency targets six-month review of such supplements, rather than the 10 months provided under BsUFA II.

Biosimilars Regulation
See All

Company Information

UsernamePublicRestriction

Register